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Abbreviations 
 
ACh, Acetylcholine 
AdipoR, adiponectin receptor 
AMPK, 5' adenosine monophosphate-activated protein kinase 
CAMKII, Ca
2+
 calmodulin kinase II 
DMEM, Dulbecco’s modified Eagle’s medium 
EGTA, ethylene glycol tetraacetic acid 
eNOS, endothelial nitric oxide synthase 
ERK1/2, extracellular-signal-regulated kinases 
FURA-2/AM, Fura-2/acetoxymethyl ester 
L-NAME, Nω-nitro-L-arginine methyl ester 
MAPK, mitogen-activated protein kinase 
NCX, Na
+
/ Ca
2+
 exchanger  
NO, nitric oxide 
NOS, nitric oxide synthase 
PAE, porcine aortic endothelial cells  
PI3K, phosphatidylinositol 3′-kinase 
PKA, protein kinase A 
PMCA, Plasma Membrane Calcium ATPase 
SERCA, sarco/endoplasmic reticulum Ca
2+
 ATPase 
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Abstract  
 
Aims: Perivascular adipose tissue can be involved in the process of cardiovascular pathology 
through the release of adipokines, namely adiponectins. Monomeric adiponectin has been shown to 
increase coronary blood flow in anesthetized pigs through increased nitric oxide (NO) release and 
the involvement of adiponectin receptor 1 (AdipoR1). The present study was therefore planned to 
examine the effects of monomeric adiponectin on NO release and Ca
2+
 transients in porcine aortic 
endothelial cells (PAE) in normal/high glucose conditions and the related mechanisms.  
Main methods: PAE were treated with monomeric adiponectin alone or in presence of intracellular 
kinases blocker, AdipoR1 and Ca
2+
-ATPase pump inhibitors. The role of Na
+
/Ca
2+
 exchanger was 
examined in experiments performed in zero Na
+
 medium. NO release and intracellular Ca
2+ 
were 
measured through specific probes.  
Key findings: In PAE cultured in normal glucose conditions, monomeric adiponectin elevated NO 
production and [Ca
2+
]c. Similar effects were observed in high glucose conditions, although the 
response was lower and not transient. The Ca
2+
 mobilized by monomeric adiponectin originated 
from an intracellular pool thapsigargin- and ATP-sensitive and from the extracellular space. 
Moreover, the effects of monomeric adiponectin were prevented by kinase blockers and AdipoR1 
inhibitor. Finally, in normal glucose condition, a role for Na
+
/ Ca
2+
 exchanger and Ca
2+
-ATPase 
pump in restoring Ca
2+
 was found.  
Significance: Our results add new information about the control of endothelial function elicited by 
monomeric adiponectin, which would be achieved by modulation of NO release and Ca
2+
 transients. 
A signalling related to Akt, ERK1/2 and p38MAPK downstream AdipoR1 would be involved. 
. 
 
Keywords 
Adipokine; AdipoR1; calcium transients; nitric oxide 
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1. Introduction 
Adiponectin, a protein which in humans is encoded by the ADIPOQ gene, is the most 
abundant adipokine produced and secreted by perivascular adipose tissue (PVAT).  
Primarily three isoforms have been detected in plasma: a low molecular weight trimer 
(LMW), a medium molecular weight hexamer (MMW) and a high molecular weight form (HMW). 
In addition, fragments from adiponectin proteolysis, including the globular domains, could also be 
found in the plasma [1]. Of these forms, the HMW has been shown to be the most active one and 
the most clinically relevant in terms of protective effects against vascular diseases and metabolic 
syndrome [2]. Hence, plasma adiponectin levels have been found to be decreased in obesity, insulin 
resistance, and type2 diabetes [3-5].  
In addition to improving insulin sensitivity, oxidative stress and inflammation [6], in vitro 
studies have shown that globular adiponectin can exert protection against endothelial dysfunction 
through a cAMP/protein kinase A (PKA)-dependent signalling [7-9]. Moreover, globular 
adiponectin has been recognized to affect angiogenesis and endothelial function through the 
activation of an endothelial nitric oxide synthase (eNOS)-related signaling pathway [10-12]. In 
endothelial cells, globular adiponectin has also been found to increase nitric oxide (NO) production 
by the involvement of its specific receptors, adiponectin receptor (AdipoR), and the 
phosphatidylinositol 3′-kinase (PI3K) activation [13, 14]. 
Changes of NO release have been shown to be involved in endothelial dysfunction such as 
that caused by high-glucose condition. Published in vitro data have shown that globular adiponectin 
could attenuate high glucose-induced oxidative stress in human umbilical vein endothelial cells by 
increasing NO secretion and phosphorylation of Akt, 5' adenosine monophosphate-activated protein 
kinase (AMPK), and eNOS [15]. Similar results were obtained in human mesangial cells [16]. 
Among various adiponectin isoforms, the monomeric one has been shown to exert 
cardioprotective effects. Hence, in anesthetized pigs, human monomeric adiponectin was able to 
cause a dose-related increase of coronary blood flow through augmented coronary NO release and 
the involvement of the subtype 1 of AdipoR (AdipoR1)  [17]. Since eNOS is a Ca2+ dependent 
enzyme, it could be hypothesized that changes in Ca
2+ 
handling could be involved in those effects 
[18]. Regarding this issue it is notable that in C2C12 myocytes adiponectin was found to increase 
the intracellular Ca
2+ 
concentration by acting on a pool of extracellular origin and through the 
involvement of AdipoR1 [19]. 
On the ground of the above issues, the present study was planned to examine the effects of 
monomeric adiponectin on NO release in normal and high glucose conditions and the mechanisms 
involved in porcine aortic endothelial cells (PAE). In particular, we focused on cAMP/PKA, Ca
2+
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5 
calmodulin kinase II (CaMKII) pathways and extracellular-signal-regulated kinases (ERK1/2), Akt 
and p38 mitogen-activated protein kinase (MAPK) involvement. The effects of monomeric 
adiponectin on Ca
2+ 
movements have also been examined. 
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2. Materials and methods 
 
2.1. Culture of PAE 
 
The experiments were performed in high and normal glucose conditions. A 30 mM 
concentration of culture fluid containing D-glucose was applied to the hyperglycemic group. PAE 
were purchased from Cell Applications, Inc. (San Diego, CA, USA) and were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM; Sigma, Milan, Italy) supplemented with 10% fetal 
bovine serum (FBS; Euroclone, Pero, Milan, Italy), 2 mM L-glutamine (Sigma), 1% penicillin-
streptomycin (Sigma), 1% HEPES (Euroclone) at 37°C with 5% CO2 in incubator. PAE (1.5 x 10
6
 
cells/ml) were plated into a 96-well plate (1 x 10
4
 cells/well) with DMEM 10% FBS supplemented 
with L-glutamine, penicillin-streptomycin, HEPES overnight (100μl/well).  
 
2.2. NO production 
 
The NO production was measured in PAE’s culture supernatants using the Griess method 
(Promega, Milan, Italy), which indirectly quantifies NO level, by measuring both NO
2-
 and NO
3-
. 
[20].  
Cells plated in 96-well plates in starvation medium were treated for 60 s, 120 s, 180 s, 240 s, 
300 s with monomeric adiponectin (0.3 ng, 3 ng, 30 ng, 100 ng; Sigma) in the concentration-related 
and time-course studies. In addition, in other cell samples, 600 s monomeric adiponectin (30 ng; 
Sigma) was given alone or in presence of the adenylyl cyclase blocker 2′5′-dideoxyadenosine (1 
μM; for 15 min; Sigma), the selective cAMP-dependent PKA inhibitor H89 (1 μM; for 15 min; 
Sigma), the NOS blocker Nω-nitro-L-arginine methyl ester (L-NAME; 10 mM; for 15 min; Sigma), 
the p38 MAPK inhibitor SB203580 (1 μM, for 30 min; Sigma), the PI3K inhibitor wortmannin (100 
nM, for 30 min; Sigma), the MAPK/ERK inhibitor UO126 (10 μM, for 30 min; Sigma), the 
CaMKII inhibitor KN93 (100 nM, for 15 min; Sigma), the AdipoR1 blocker GTX89956-PEP (30 
ng, for 15 min; GeneTex; Irvine, CA, USA). Acetylcholine chlorohydrate (10 mM, for 1 min; 
Sigma) was used as positive control. The agonist–antagonists and their vehicle were also tested in 
the basal medium without agents. H89, 2′5′-dideoxyadenosine, L-NAME, SB203580, wortmannin, 
UO126 and KN93 were used at similar concentrations as those that were able to prevent the effects 
of intermedin 1-47, human chorionic gonadotropin, urocortin II and levosimendan in endothelial 
cells [21-24].  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
 
7 
At the end of the stimulations, NO production in the sample's supernatants was examined by 
adding an equal volume of Griess reagent following the manufacturer's instruction. At the end of 
incubation, the absorbance at 570 nm was measured by a spectrometer (BS1000 Spectra Count, San 
Jose, CA, USA) and the NO production was quantified in respect to nitrite standard curve and 
expressed as percentage. The values obtained corresponded to the NO (μmol) produced, after each 
stimulation, by samples containing 1.5 μg of proteins each. 
 
 
2.3. Cytosolic calcium ([Ca
2+
]c) measurement 
 
The coverslips were washed twice with sterile PBS 1X and starved with DMEM 0% FBS for 
4 hours. After that they were incubated with Fura-2/acetoxymethyl ester (AM; 5 µM final 
concentration; Sigma) for 30-40 min in the dark in DMEM 0% FBS and without red phenol 
supplemented with 1% penicillin-streptomycin, 1% HEPES and 2 mM L-glutamine.  
First we performed a study about dose-dependent effects of monomeric adiponectin on Ca
2+
 
movements in both normal and high glucose conditions. Then, we examined the origin of the Ca
2+
 
pool mobilized by monomeric adiponectin in normal glucose condition by performing the 
experiments in the presence or absence of ethylene glycol tetraacetic acid (EGTA, 50 mM; Sigma) 
or by treating PAE with agents which act through IP3 generation like adenosine triphosphate (ATP, 
10 µM; Sigma) and thrombin (100 U/ml; Sigma), administrated either before or after adiponectin. 
These experiments were performed in order to examine if the intracellular pool affected by 
monomeric adiponectin was IP3-dependent. In this case different responses of PAE to monomeric 
adiponectin given before/after ATP or thrombin would be expected. Moreover, some experiments 
were performed in PAE cultured in normal glucose condition by monomeric adiponectin 
administration in absence or presence of H89 (1 µM; Sigma), GTX89956-PEP (30 ng; GeneTex) 
and KN93 (1 µM; Sigma). H89 and KN93 were used at similar concentrations that were able to 
prevent the effects of gastrin 17 and urocortin II  in PAE [25, 26].  
In cells, the major Ca
2+
 entry pathway is the store-operated one, in which the emptying of 
intracellular Ca
2+
 stores activates Ca
2+
 influx (“capacitative” calcium entry). The effects of 
monomeric adiponectin on the “capacitative” Ca2+ entry through the plasma membrane Ca2+ 
channels were examined through the evaluation of the rate of Ca
2+
 overshoot in PAE in normal and 
high glucose conditions. The cells on coverslips were pretreated with EGTA (50 mM) and were 
subsequently exposed to the Ca
2+
 ATPase inhibitor, thapsigargin (1 µM; Sigma), and monomeric 
adiponectin alone or in co-stimulation..  
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Since the return of [Ca
2+
]c to control values was shown to be related to the activation of the 
Na
+
/Ca
2+
 exchanger (NCX) and PMCA (Plasma Membrane Calcium ATPase) in vascular 
endothelial cells [25, 26], we performed some experiments in order to examine their role in both 
normal and high glucose conditions. To achieve this purpose, PAE were incubated in zero Na
+
 PSS 
[N-methyl-d-glucamine (NMDG) 126 mM, KCl 1.5 mM, MgCl2 1.2 mM, HEPES 10 mM, d-
glucose 10 mM, and CaCl2 mM, Sigma], as previously performed [25, 26]. Moreover, in some 
experiments, monomeric adiponectin was administered in zero Na
+
 PSS in presence of PMCA 
inhibitor, carboxyeosin diacetate (25 μM; Invitrogen, San Giuliano Milanese, Italy).  
 
 
3. Statistical analyses 
 
All data were recorded using the Institution's database. Statistical analysis was performed by 
using STATVIEW version 5.0.1 for Microsoft Windows (SAS Institute Inc., Cary NC, USA). Data 
were checked for normality before statistical analysis. Quantification of [Ca
2+
]c was conventionally 
obtained by measuring the Fura-2/AM fluorescence in Ca
2+ 
free (0.1 M EGTA) and Ca
2+
 saturated 
conditions by the equation [Ca
2+
]c = Kd [(RRmin)/(Rmax-R). The fluorescence intensities obtained 
were corrected for cell autofluorescence at the wavelengths employed. All the results obtained were 
examined through one-way ANOVA followed by Bonferroni post hoc tests, which were used to 
examine changes in NO and Ca
2+
 caused by various agents among the groups. The non-parametric 
Mann Whitney U test for unpaired data was used to compare percentage responses. A simple-
regression analysis was performed to examine the correlation between the concentration of 
monomeric adiponectin administered and the observed NO and [Ca
2+
]c effects in the concentration-
response study. All data are presented as means ± SD of five independent experiments for each 
experimental protocol. A value of p<0.05 was considered statistically significant. 
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4. Results 
 
4.1. Dose-response effects of monomeric adiponectin on NO release in PAE in normal and high  
glucose conditions 
 
As illustrated in Fig.1A, in the time-course study performed in normal glucose condition, 
monomeric adiponectin (0.3 ng, 3 ng, 30 ng, 100 ng) increased NO release in a dose-dependent way 
(p<0.05; R: 0.81, 0.78, 0.71, 0.82). Also in PAE cultured in high glucose condition, monomeric 
adiponectin (0.3 ng, 3 ng, 30 ng, 100 ng) was able to increase NO production although to a lower 
extent relative to what was observed in normal condition. Moreover, a steady-state was reached 
(Fig. 1B). It is to note that the presence of endothelial dysfunction in high glucose conditions was 
confirmed by the results obtained by using acethylcholine, which was able to cause NO release of 
about 12% only. Since in the normal glucose condition, the highest effects of monomeric 
adiponectin were obtained at 30 ng, we have chosen that dose for all next experiments performed 
about NO release. 
 
4.2. Mechanisms involved in NO release caused by monomeric adiponectin in PAE in normal 
glucose condition 
 
The effects of various inhibitors alone on NO release in both normal and high glucose 
conditions are shown in Fig. 1 of Supplemental material. In normal glucose condition, treatment 
with inhibitors abolished the effects of adiponectin on NO release in PAE (Fig. 2A). Also in PAE 
cultured in high glucose the effects of monomeric adiponectin were abolished by H89, KN93, 
GTX89956-PEP  and wortmannin, while SB203580 and UO126 were only able to reduce them 
(Fig. 2B).  
 
4.3. Dose-response effects of monomeric adiponectin on [Ca
2+
]c in PAE in normal and high glucose 
condition 
 
In PAE cultured in normal glucose medium, monomeric adiponectin (0.3 ng, 3 ng, 30 ng, 
100 ng), caused a dose-related and transient [Ca
2+
]c increase (p<0.05; Fig. 3, Table 1). Those results 
were linearly correlated to the dose of adiponectin administrated (R: 0.74, 0.89, 0.87, 0.53). The 
highest effect was virtually obtained with 30 ng adiponectin for 60 s stimulation, and this 
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concentration was maintained for all successive experiments. In contrast, the effects of monomeric 
adiponectin in high glucose condition were lower and not transient (Fig. 4; Table 1). 
 
4.3.1 Analysis of Ca
2+
 pool mobilized by monomeric adiponectin in PAE and mechanisms involved 
in normal glucose condition 
 
As reported in Table 2, the effects of monomeric adiponectin on [Ca
2+
]c were practically 
abolished in PAE cultured in Ca
2+
-free medium. The noncompetitive inhibitor of the 
sarco/endoplasmic reticulum Ca
2+
 ATPase (SERCA), thapsigargin (1 μM), caused a persistent 
increase of  [Ca
2+
]c, which at 1 min from the start of administration amounted to 132.5 ± 2.2 nM 
from control values of 100.4 ± 3.3 nM (Fig. 5A). The addition of 30 ng monomeric adiponectin in 
co-stimulation with thapsigargin markedly changed the kinetics of cytosolic Ca
2+
 fluctuations 
promoted by thapsigargin. Hence, at 1 min and 5 min from the beginning of thapsigargin 
administration, [Ca
2+
]c amounted to 126.8 ± 2.6 nM and 122.6 ± 3 nM (Fig. 5B), respectively. 
Those values were lower than the ones found with thapsigargin alone (p<0.05). These results 
demonstrated that monomeric adiponectin caused an increase of [Ca
2+
]c by promoting Ca
2+
 
mobilization from a pool mainly of extracellular origin and by modulating “capacitative Ca2+ 
entry”. 
In order to achieve more details on the nature of the intracellular store affected by 
monomeric adiponectin, experiments were performed using extracellular ATP (10 μM) and 
thrombin (0.5 U/ml), which mobilize Ca
2+
 from an IP3-sensitive pool  [25, 26]. Those agents were 
administrated either before or after adiponectin. As reported in Fig.5C and D, the pool mobilized by 
monomeric adiponectin was partly similar to the one affected by ATP. 
When ATP was given after monomeric adiponectin, [Ca
2+
]c amounted to 123.9 ± 2.9 nM 
from control values of 107 ± 2 nM. When ATP was given before adiponectin, [Ca
2+
]c amounted to 
130 ± 1.31 nM from control values of 107 ± 2.1 nM. Also the effects of monomeric adiponectin on 
[Ca
2+
]c differed in relation to order of administration. When adiponectin was given before ATP,  
[Ca
2+
]c amounted to 114.5 ± 2.9 nM
 
from control values of 106.2 ± 2.1 nM. When adiponectin was 
given after ATP,  [Ca
2+
]c amounted to 111.2 ± 1.3 nM from control values of 105 ± 1.5 nM. 
Different results were obtained with thrombin. Hence, the increase of [Ca
2+
]c caused by 
monomeric adiponectin and thrombin did not significantly differ irrespective of the sequence of 
addition (Fig. 5E and F and Table 2). 
The fact that the response of PAE to monomeric adiponectin and to an agent acting through 
IP3 generation, like ATP, differs in relation to the sequence of addition, suggests that monomeric 
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adiponectin would act through an IP3-related signalling, which is however somehow different from 
that affected by another IP3-dependent Ca
2+ 
 mobilizing agent, like thrombin. 
As shown in Fig. 6A-C, the effects of monomeric adiponectin on [Ca
2+
]c in PAE cultured in 
normal glucose condition, were almost abolished by KN93, H89 and GTX88956-PEP, which 
demonstrated the involvement of PKA, CaMKII and AdipoR1 pathways.  
As the NCX and PMCA have been shown to contribute to lower [Ca
2+
]c in vascular 
endothelial cells [7, 25-27] experiments were performed to abolish their contribution to Ca
2+
 
extrusion. In PAE cultured in Na
+
 free medium (Na
+
PSS) and normal glucose condition with or 
without PMCA blocker, the effects of monomeric adiponectin were markedly changed, being the 
decay phase mainly affected. As shown in Fig. 6D and E and reported in Table 3 the increase of 
[Ca
2+
]c was lower and had not returned to control values at 5 min from the start adiponectin 
administration. In PAE treated with carboxyeosin acetate, a plateau in the effects of adiponectin was 
reached.  
 
4.4.2 Analysis of Ca
2+
 pool mobilized by monomeric adiponectin in PAE in high glucose condition. 
Role of ” Capacitative Calcium entry”, NCX and PMCA and AdipoR1 
 
The effects of monomeric adioponectin on [Ca
2+
]c cultured in Na
+
PSS with or without 
carboxyeosine acetate were not different from those previously observed during the grading  study 
(Fig. 7A and B; Table 3). 
As shown in Fig. 7C and D, in presence of EGTA, monomeric adiponectin failed to affect 
Ca
2+
 movements in PAE cultured in high glucose condition. Moreover, the response of PAE to 
thapsigargin was changed by monomeric adiponectin. At 1 min, the increase of [Ca
2+
]c caused by 
thapsigargin alone reached a plateau value of  122 ± 3.7 nM  from control values of 99.6 ± 2.8 nM 
(Fig. 7C). When monomeric adiponectin was given with thapisgargin, at 1 min from the beginning 
of thapsigargin administration, [Ca
2+
]c amounted to 110.4 ± 2.4 nM from control values of 97.8 ± 
3.2 nM. At 5 min from the start thapsigargin, the [Ca
2+
]c was almost returned to basal values (Fig. 
7D).   
These results demonstrated that in high glucose conditions the Ca
2+
 pool mobilized by 
monomeric adiponectin was of extracellular origin and highly independent from the thapsigargin-
sensitive one. 
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5. Discussion 
 
The results of this study have shown for the first time in PAE that monomeric adiponectin 
increases NO release in both normal and high glucose conditions to a different extent and through a 
different modulation of Ca
2+
 movements. A role for intracellular signalling involving kinases 
leading to NOS phosphorylation and AdipoR1 has been highlighted.  
All previous studies have been mainly focused on vascular effects of the principal isoforms 
adiponectin [1]. Those findings have generally shown protective effects on endothelial function, 
which were achieved through the enhancement of NO release and the involvement of PKA, PI3K 
and eNOS [2]. Also in oxidative stress conditions caused by high glucose medium, adiponectin was 
found to exert protection through elevated eNOS-related NO production and Akt and AMPK 
activation [28]. Those results could account for cardiovascular protection exerted by adiponectins in 
insulin resistance and diabetic conditions [10-12]. Relevant to this issue are the findings that 
endothelial dysfunction is present in a number of cardiovascular conditions such as diabetes, 
hypercholesterolemia and hypertension and seems to be an important feature in the pathogenesis of 
the atherosclerotic disease process [29]. Endothelial dysfunction could be assumed to be attributable 
to a nitroso-redox imbalance which is characterized by decreased endothelium-dependent 
vasorelaxation and changes in coagulation and inflammatory response. Decreased NO 
bioavailability appears to be central to the pathogenesis of this condition  [30]. 
The results obtained in the present study have shown for the first time that monomeric 
adiponectin can increase NO release in PAE by affecting Ca
2+
 movements although in a different 
way depending on normal and high glucose conditions. The doses of monomeric adiponectin used 
in PAE were similar to those shown in anesthetized pigs to increase coronary blood flow and 
cardiac function [31]. 
While in PAE cultured in normal glucose medium the effects of monomeric adiponectin 
were linearly related to the infused dose and did not reach a steady state, in high glucose medium 
the response of PAE was lower and reached a plateau. It is to note that findings obtained in normal 
glucose conditions are in agreement with observations from anesthetized pigs in which the coronary 
effects caused by monomeric adiponectin were linearly related to coronary NO release [17]. Also in 
this study the Griess system was used for NO detection, as previously performed in same or similar 
cellular model [31-34]. 
The analysis of intracellular pathways involved in the effects of monomeric adiponectin in 
PAE in normal and high glucose condition has revealed a role of cAMP/PKA, CAMKII, ERK1/2, 
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p38MAPK, Akt and NOS. Hence, all effects of monomeric adiponectin on NO release were 
abolished or reduced by specific blockers of above kinases [31-34]. 
In addition, GTX88956-PEP, the AdipoR1 blocker, was able to inhibit the effects of 
monomeric adiponectin. AdipoR1 belongs to the family of adiponectin receptors, AdipoRs [35], 
which includes two seven transmembrane domain receptors, AdipoR1 and AdipoR2 [36]. We have 
chosen AdipoR1 in our study because in contrast to AdipoR2 its expression is ubiquitous and has 
been reported to be highly present in pig tissues [37]. Moreover, also in anesthetized pigs the 
cardiac and vascular effects of monomeric adiponectin were related to AdipoR1, being abolished by 
GTX88956-PEP [27].  
Thus, at the basis of the effects of monomeric adiponectin on NO release there would be the 
activation of an intracellular signalling leading to Akt, ERK1/2, p38MAPK activation and NOS 
phosphorylation, downstream AdipoR1 and cAMP. Our findings are in agreement with previous 
ones about the role of those kinases and pathways in the effects of adiponectins on NO and add 
more information about their involvement in mediating the effects of various isoforms of peptide 
[38]. Hence, while Akt and AdipoR1 would play a role in eliciting the response of cells to almost all 
adiponectin isoforms, p38MAPK would be only involved as an intracellular mediator of the effects 
of the globular and monomeric ones [38]. 
Also the results obtained in high glucose condition are in agreement with previous 
observations found in human umbilical vein endothelial cells, where globular adiponectin was able 
to prevent the reduction of NO release caused by intermittent or constant high glucose [39]. 
Furthermore, the findings of an involvement of PKA, p38MAPK and Akt in mediating the 
effects of monomeric adiponectin on NO release in high glucose condition could assume clinical 
relevance; those mechanisms have been reported to play a role in inflammatory signal generation 
triggered by high glucose [39]. 
Changes of [Ca
2+
]c levels are of primary importance in the regulation of NO production. 
Hence, the constitutive isoform of NOS present in endothelial cells (eNOS) is Ca
2+
 dependent [40] 
and [41]. For this reason we aimed to examine the effects of monomeric adiponectin on Ca
2+
 
movements in PAE in both normal and high glucose conditions. 
As for NO release, firstly we have performed a dose-dependent study by analyzing the 
effects of monomeric adiponectin on [Ca
2+
]c in Fura 2-AM loaded PAE. Our results have shown for 
the first time that while in normal glucose conditions the effects of monomeric adiponectin on 
[Ca
2+
]c are dose-related and transient, in high glucose condition the increase of [Ca
2+
]c is lower and 
reaches a steady-state.  
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Then, we examined the origins of the Ca
2+
 pool mobilized by monomeric adiponectin and 
the mechanisms involved. In the cytosol, Ca
2+
 is maintained at a very low level and is concentrated 
in intracellular calcium stores such as the endoplasmic reticulum [42]. The dynamic steady state of 
Ca
2+
 in the cytosol is the result of the balance between active and passive fluxes through the cell 
membranes of various stores and is strictly regulated [43, 44]. In particular, the release from 
intracellular pools may occur as a consequence of IP3 generation. Also, the release of intracellular 
Ca
2+
 coupled to subsequent Ca
2+
 entry, known as “capacitative Ca2+ entry”, is a mechanism widely 
reported to affect Ca
2+
 homeostasis in response to various stimuli [45, 46].   
Experiments performed with PAE in normal glucose condition and in presence of EGTA, 
ATP and thrombin have shown that the Ca
2+
 pool mobilized by monomeric adiponectin was of 
extracellular origin and independent from that mobilized by an agent acting through IP3 generation, 
like ATP [47]. Those results confirmed previous ones in C2C12 [19]. 
Moreover, and as observed about NO release, the effects of monomeric adiponectin on 
[Ca
2+
]c were abolished by H89, KN93 and GTX88956-PEP, which showed the involvement of a 
signalling PKA- and CAMKII-related downstream AdipoR1.  
Thus, it could be assumed that in normal glucose condition, monomeric adiponectin would 
cause NO release by increasing [Ca
2+
]c through a common pathway involving AdipoR1 and 
intracellular signalling. 
We have further examined the role of “capacitative” Ca2+ entry, NCX and PMCA in the 
effects of monomeric adiponectin in both normal and high glucose conditions. We focused on those 
mechanisms in an attempt to explain the observed differences in Ca
2+
 movements found in different 
glucose media and because those mechanisms have been reported to be variably affected in the 
diabetic condition [48]. 
When comparing the effects of thapsigargin, the non-competitive inhibitor of SERCA, on 
[Ca
2+]c in normal and high glucose conditions, it was quite clear that the “capacitative Ca2+ entry” 
would play a greater role in the effects of monomeric adiponectin in the latter condition. Hence, 
while in normal glucose conditions monomeric adiponectin was able to only reduce the effects of 
thapsigargin, in high glucose ones the response of PAE to thapsigargin was markedly changed.  
The activation of the plasma membrane PMCA and of NCX would also play an important 
role in the restoration of basal intracellular [Ca
2+
]c in PAE [25, 26]. In experiments performed in 
PAE cultured in Na
+
-free normal glucose conditions, the decay phase of the adiponectin-evoked 
Ca
2+
 transient was significantly longer. Moreover, in PAE cultured in Na
+
-free medium and loaded 
with carboxyeosin, the specific PMCA pump inhibitor, the effects of monomeric adiponectin on 
[Ca
2+
]c transient reached a plateau. Thus, the results obtained showed that in normal glucose 
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conditions during the decay phase of the [Ca
2+
]c transient, Ca
2+
 was extruded by both the PMCA 
pump and by NCX. 
 
In contrast, the results obtained in high glucose medium showed that neither NCX nor 
PMCA would be involved in the effects of monomeric adiponectin. These findings could be in 
agreement with previous observations showing altered function of NCX and/or PMCA in diabetic 
conditions [48]. 
 
6. Conclusions 
  
Our findings indicate that monomeric adiponectin increases NO release in PAE cultured in 
both normal and high glucose conditions through a signalling involving Akt, ERK1/2 and 
p38MAPK downstream AdipoR1. Those effects would be related to changes in Ca
2+
 transients, 
which would arise from modulation of Ca
2+
 influx from extracellular space and the release from 
intracellular thapsigargin-sensitive Ca
2+
 stores. Our results add new information about the control of 
endothelial function elicited by monomeric adiponectin in both physiological and pathological 
conditions. In this context, monomeric adiponectin would play a beneficial role by acting as a 
paracrine agent in the keeping of endothelial function and prevention of endothelial damage caused 
by high glucose condition. Moreover, our findings could increase the knowledge about the role 
played by PVAT in modulation of vascular function through the release of adipokines. Further in 
vivo experiments will be mandatory to predict clinically advantageous effects of monomeric 
adiponectin. 
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Figure legends 
 
Fig. 1. Effects of monomeric adiponectin on NO release in PAE in normal (A) and high (B) 
glucose conditions. In A, in the time-course study in normal glucose conditions, monomeric 
adiponectin (0.3 ng, 3 ng, 30 ng, 100 ng) increased NO release in a dose-dependent way. In B, in 
high glucose conditions the effects of monomeric adiponectin (0.3 ng, 3 ng, 30 ng, 100 ng) were 
lower than those found in high glucose. NO is expressed as % of basal values and  corresponds to 
the NO (μmol) produced, after each stimulation, by samples containing 1.5 μg of proteins each. 
Reported data are mean ± SD of five independent experiments. 
 
Fig. 2. Effects of monomeric adiponectin in PAE in NO release in presence or absence of 
various agents. In A, and B effects of 600 s monomeric adiponectin in normal and high glucose 
conditions on NO release expressed as % of basal values. C= control values; A= monomeric 
adiponectin (30 ng); 2’5’= 2’5’ dideoxyadenosine (1 µM); H89= H89 (1 µM); KN93= KN93 (1 
µM); GTX89956= AdipoR1 Blocker (30 ng); Wort= wortmannin (100 nM); SB203580= SB203580 
(1 µM); UO126 = UO126 (10 µM); L-NAME= L-NAME (10 mM); ACh= acetylcholine (10 mM). 
Reported data are mean ± SD of five independent experiments * p<0.05 vs C; # p<0.05 vs A (30 
ng). 
 
Fig. 3. Dose-response effects of monomeric adiponectin on [Ca
2+
]c in PAE in normal glucose 
conditions. Dose-response and time-course study and an example taken from one of five 
experiments are shown. Monomeric adiponectin (0.3 ng, 3 ng, 30 ng, 100 ng), caused a dose-related 
and transient [Ca
2+
]c increase. The results are the mean ± SD of 5 experiments. The abbreviations 
are as in previous figures. 
 
Fig. 4. Dose-response effects of monomeric adiponectin on [Ca
2+
]c in PAE in high glucose 
conditions. Dose-response and time-course study and an example taken from one of five 
experiments are shown. Monomeric adiponectin (0.3 ng, 3 ng, 30 ng, 100 ng), caused a lower but 
not transient effect. The results are the mean ± SD of 5 experiments. The abbreviations are as in 
previous figures. 
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21 
Fig. 5. Analysis of intracellular Ca
2+ 
pool mobilized by monomeric adiponectin in PAE in 
normal glucose conditions. In A and B, effects of monomeric adiponectin on thapsigargin-
dependent Ca
2+
 pool. In C and D, effects of monomeric adiponectin on ATP-dependent Ca
2+
 pool. 
In E and F, effects of monomeric adiponectin on thrombin-dependent Ca
2+
 pool. An example of 
each experimental protocol is shown. In A, thapsigargin (SERCA inhibitor, 1 μM) alone. In B 
monomeric adiponectin (A 30 ng) with thapsigargin; EGTA (50 mM). In C and D, ATP was 
administrated either before or after monomeric adiponectin. In E and F, monomeric adiponectin was 
administrated before or after thrombin. The results are the mean ± SD of 5 experiments for each 
experimental protocol.  
 
Fig. 6. Effects of monomeric adiponectin in PAE in presence of various agents and role of 
NCX and PMCA in the effects of monomeric adiponectin in normal glucose conditions. In A-
C, effects of monomeric adiponectin (A 30 ng) in presence of KN93 (1 µM), H89 (1 µM) and 
GTX899565-PEP (30 ng). In D and E, effects of monomeric adiponectin  (A 0.3 ng and A 100 ng) 
on [Ca
2+
]c in PAE incubated in Na
+
PSS in the absence or presence of carboxyeosin diacetate (25 
μM) are shown. Each example was taken from one of the five different experiments for each 
experimental protocol. Car E, carboxyeosin diacetate.  
 
Fig. 7. Role of NCX and PMCA in the effects of monomeric adiponectin on Ca
2+
 movements 
and effects of monomeric adiponectin on thapsigargin-dependent Ca
2+ 
pool in high glucose 
conditions. In A and B, effects of monomeric adiponectin  (A 0.3 ng and A 100 ng) on [Ca
2+
]c in 
PAE incubated in Na
+
PSS in the absence or presence of carboxyeosin diacetate (25 μM) are shown. 
In C and D, effects of monomeric adiponectin on thapsigargin-dependent Ca
2+
 pool. An example 
was taken from one of the five different experiments for each experimental protocol. Car E, 
carboxyeosin diacetate.  
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Table 1. Effects of monomeric adiponectin on [Ca
2+
]c in PAE 
 
 
 
 
 
 
In Table, the effects on [Ca
2+
]c caused by monomeric adiponectin at 60 s stimulation, are shown. 
Data are means ± DS of 5 different experiments for each experimental protocol. A= monomeric 
adiponectin. 
*
p<0.05 vs C (Control); #  p<0.05 vs A 0.3 ng; † p<0.05 vs A 3 ng; a p <0.05 vs high 
glucose.  
 
 
 NORMAL GLUCOSE HIGH GLUCOSE 
C  104 ± 1.6 nM 101.4± 2.3 nM 
A 0.3 ng  108.8 ± 1
*
 
a  
nM 105.8± 1.4
*
 nM 
A 3 ng  111.2 ± 0.8
*#a 
nM 107.8 ± 0.8
*# 
nM 
A 30 ng  114 ± 1.2
*#†a 
nM 109.2 ± 1.6
*#  
nM 
A 100 ng  117 ± 1.5
*#†a 
nM 110.2± 1.5
*#  
nM 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
 
31 
Table 2. Effects of monomeric adiponectin on [Ca
2+
]c in presence/absence of various agents  in 
PAE 
 
THR (0.5U/ml) PRE A 30 ng/ml 131 ± 2.4
* 
nM 
C 105.6 ± 2.4 
 
nM 
KN93 100.2 ± 2.5
* 
nM 
KN93 + A 30 ng/ml 100.8 ± 2.6
* 
nM 
C 106.6 ± 2.4 
 
nM 
H89 101.6 ± 2
*  
nM 
H89 + A 30 ng/ml 102.2 ± 2.7
*  
nM  
C 105 ± 3.3 nM 
GTX89956-PEP 106.6 ± 3.8 
 
nM 
  
NORMAL 
GLUCOSE 
C 99.6 ± 3.3 nM 
A 30 ng/ml 112.2 ± 2.2
* 
nM 
C 106.9 ± 1.7 nM 
EGTA + A 30 ng/ml 102 ± 2.2
*  
nM 
C 106.2 ± 2.1 nM 
A 30 ng/ml PRE THR (0.5U/ml) 115 ± 1.7
* 
nM 
C 106.3 ± 1.9 nM 
A 30 ng/ml  POST THR (0.5U/ml) 115.6 ± 1.4
* 
nM 
C 105.3  ± 1.2 nM 
THR (0.5U/ml) POST A 30 ng/ml  130.8 ± 2.8
* 
nM 
C 105.8 ± 1.6 nM 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
 
32 
 
 
In Table, the effects on [Ca
2+
]c caused by monomeric adiponectin at 60 s stimulation, in 
presence/absence of various agents are shown. Data are means ± DS of 5 different experiments for 
each experimental protocol. A= monomeric adiponectin, THR=Thrombin 
*
p<0.05 vs Control.  
 
GTX89956-PEP + A 30 ng/ml 106.4 ± 4.1
 
nM 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
 
33 
Table 3. Effects of monomeric adiponectin on [Ca
2+
]c in PAE cultured in  normal  and high 
glucose medium- Na
+
 PSS alone or with carboxyeosin diacetate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Table, the effects on [Ca
2+
]c caused by monomeric adiponectin (peak and at 5 min) Na
+
 PSS 
medium in absence or presence of carboxyeosin acetate are shown. Data are means ± DS of 5 
different experiments for each experimental protocol. Layout is as in previous Tables. 
*
p<0.05 vs 
Control; 
#
  p<0.05 vs peak; 
†  
Na
+ 
PSS alone p<0.05 vs Na
+  
PSS + carboxyeosin diacetate. 
C  102 ± 2.7 102.4 ± 3.1 
A 0.3 ng peak 107.6 ± 3.2
* †
  106.7 ± 2.9
*
  
A 0.3 ng 5 min  104 ±  2.5
*#
   
A 100 ng peak 116.2  ± 4.3*
 †
   114.2 ± 4.6
*
 
A 100 ng 5 min  111.6 ± 3
*#
   
 Na
+
 PSS 
Na
+
 PSS + CARBOXYEOSIN 
DIACETATE 
 NORMAL GLUCOSE 
C  103 ± 2.2 nM 102.8 ± 2.6 nM 
A 0.3 ng peak 107.6 ± 3.2
* †
 nM  106.4 ± 2.6
*
 nM 
A 0.3 ng 5 min  104 ±  2.5
*#
 nM  
A 100 ng peak 113.4 ± 3.2*
 †
  nM 112.6 ± 3.8
* 
nM 
A 100 ng 5 min  111.6 ± 3
*#
 nM  
 HIGH GLUCOSE 
C  101.9 ± 1.7 nM 101.6 ± 1.3 nM 
A 0.3 ng peak 107.1 ± 1.6
*† 
nM 106.8 ± 1.8
*  
nM 
A 0.3 ng 5 min  106.1 ± 1.7
*# 
nM  
A 100 ng peak 111.5 ± 1.8
*† 
nM 111.4 ± 1.3
* 
nM 
A 100 ng 5 min  110.9 ± 1.2
*# 
nM  
